The role of carfilzomib in relapsed/refractory multiple myeloma
Andrew J. Yee
Abstract
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.
Topics & Concepts
CarfilzomibDaratumumabMedicineLenalidomideBortezomibMultiple myelomaProteasome inhibitorOncologyDexamethasoneAdverse effectPomalidomideRefractory (planetary science)Internal medicinePharmacologyPhysicsAstrobiologyMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsPeptidase Inhibition and Analysis